GLP-1 Diary – Injection Log

GLP-1 side effects: what is common, what is rare, and when to get help

Nausea and constipation are very common on Mounjaro and Wegovy. Pancreatitis, gallstones and NAION are rare but urgent. How to tell them apart and who to call.

Most side effects of GLP-1 medicines are in the gut: nausea, diarrhoea, vomiting, tummy pain and constipation. In the Mounjaro weight-management trials these were very common, affecting more than 1 in 10 people, and they tend to be worst in the first weeks and after each dose increase. A handful of rare side effects need urgent attention, above all severe tummy pain that spreads to the back, which can be a sign of pancreatitis.

Knowing which is which saves you from two mistakes: ignoring something serious, or stopping a medicine in a panic because of something expected and manageable.

The common ones

The EU product information for Mounjaro groups side effects by frequency. For people treated for weight management, the "very common" (more than 1 in 10) and "common" (up to 1 in 10) lists include:

Frequency Examples
Very common Nausea, diarrhoea, vomiting, abdominal pain, constipation, fatigue
Common Indigestion, bloating, burping, wind, reflux, dizziness, low blood pressure, hair loss, injection-site reactions

The semaglutide medicines (Wegovy, Ozempic) have a similar pattern. The MHRA's GLP-1 guidance notes that gastrointestinal effects make up the majority of Yellow Card reports for these products, and that most are mild to moderate or short-lived.

The one common problem that can turn serious

The same MHRA guidance warns that nausea, vomiting and diarrhoea sometimes lead to severe dehydration that needs hospital treatment. Dehydration can also strain the kidneys. If you cannot keep fluids down, are passing very little urine, or feel faint and dizzy, contact your GP or NHS 111 the same day.

Rare but urgent

These are uncommon, but you should know the symptoms by heart.

Acute pancreatitis

On 29 January 2026 the MHRA updated product information to highlight the small risk of severe acute pancreatitis. It describes the warning signs as severe, persistent stomach pain that may radiate to the back, possibly with nausea and vomiting. Between 2007 and October 2025 the MHRA received 1,296 Yellow Card reports of pancreatitis linked to GLP-1 medicines, at a time when an estimated 1.6 million adults in Great Britain had used them for weight loss in a single year. The agency stresses that the risk is very small, but that the symptoms need urgent medical attention.

Gallbladder problems

Gallstones and gallbladder inflammation are listed as uncommon. The NHS page describes severe tummy pain as the warning sign, and France's medicines agency ANSM lists gallbladder inflammation among the effects it keeps under enhanced surveillance.

Severe allergic reaction

Rare, but an emergency. Swelling of the lips, tongue or throat, an itchy rash spreading over the body, or difficulty breathing: call 999.

Sudden vision loss (semaglutide)

In June 2025 the EMA's safety committee concluded that NAION, a type of damage to the optic nerve, is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people. If you notice sudden loss of vision or rapidly worsening eyesight, contact your doctor without delay.

Low blood sugar

Mainly a risk for people with type 2 diabetes who also take insulin or a sulfonylurea. Shakiness, sweating, confusion and a racing heart are typical signs. Your diabetes team should explain what to do.

Who to contact: a quick guide

Situation What to do
Mild nausea, constipation, tiredness Mention it at your next review or ask your pharmacist
Vomiting or diarrhoea for more than a day, signs of dehydration GP or NHS 111 the same day
Severe, persistent tummy pain, possibly into the back Urgent medical attention: NHS 111, or A&E/999 if very severe
Sudden vision loss Contact a doctor without delay
Swollen face or throat, breathing difficulty 999
Planned surgery or sedation Tell the surgical team and anaesthetist in advance

Before surgery, endoscopy or sedation

GLP-1 medicines slow stomach emptying. The MHRA warns that this increases the risk of stomach contents entering the airways under general anaesthesia or deep sedation, so the team may need to change your preparation. Always mention your GLP-1 medicine at pre-assessment, even for minor procedures.

Keeping a useful record

When you do speak to a clinician, specifics help: which symptom, how bad, which day after the injection, and whether it followed a dose increase. A side-effect log with a 1–5 severity score, like the one in GLP-1 Diary, makes patterns easy to show. A paper diary is just as good if you fill it in on the day.

Report it

Anyone can report a suspected side effect to the MHRA through the Yellow Card scheme, online or via the app. You do not need to be sure the medicine caused it. Reports are how rare risks like the ones above were spotted in the first place.

Do not stop without a plan

The NHS advises not to stop suddenly without talking to your doctor, particularly if you have diabetes, because it can affect blood sugar. If side effects are making treatment hard to continue, ask your prescriber what the options are.

Related reading: GLP-1 medicines, contraception and pregnancy and what to log before your review appointment.

GLP-1 Diary – Injection Log

Injection sites, weight, side effects and a clear report for your doctor or nurse.

Download on the App Store

Frequently asked questions

How common is nausea on Mounjaro?

Very common: the EU product information lists nausea, diarrhoea, vomiting, abdominal pain and constipation as affecting more than 1 in 10 people in the weight-management trials, mostly during dose escalation.

What are the warning signs of pancreatitis?

The MHRA describes severe, persistent stomach pain that may spread to the back, sometimes with nausea and vomiting. Seek urgent medical attention if this happens.

Should I tell my anaesthetist I take Wegovy or Mounjaro?

Yes. The MHRA advises telling your healthcare team, including the anaesthetist, before any procedure under general anaesthesia or deep sedation, because these medicines slow stomach emptying.

Sources

  1. MHRA updates guidance for GLP-1 prescribers and patients (pancreatitis) — MHRA (2026-01-29)
  2. GLP-1 medicines for weight loss and diabetes: what you need to know — MHRA
  3. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines — European Medicines Agency (2025-06-06)
  4. Mounjaro – EPAR product information, section 4.8 — European Medicines Agency
  5. Tirzepatide – side effects — NHS

More articles